9 Meters Biopharma Inc

Change company Symbol lookup

Select an option...

NMTR 9 Meters Biopharma Inc

RONI Rice Acquisition Corp II

SUP Superior Industries International Inc

NECB Northeast Community Bancorp Inc

NIDB Northeast Indiana Bancorp Inc

SPXC SPX Technologies Inc

ULTA Ulta Beauty Inc

HTGM HTG Molecular Diagnostics Inc

MLEC Moolec Science SA

GDHG Golden Heaven Group Holdings Ltd

Go

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.